FMT in Initial CDI

Launched by TURKU UNIVERSITY HOSPITAL · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called fecal microbiota transfer (FMT), which involves using a retention enema to help patients recover from their first episode of Clostridioides difficile infection (CDI). CDI is a serious infection that can cause severe diarrhea and other intestinal issues. The goal of the study is to see if this method can improve recovery and prevent future infections.

To be eligible for this trial, you need to be at least 18 years old and have tested positive for C. difficile in your stool while experiencing symptoms. You should also have had your diarrhea completely resolve during antibiotic treatment for C. difficile and not be receiving any other antibacterial treatments or probiotics. Participants will need to sign a consent form to be part of the study. It's important to note that pregnant individuals, those requiring ongoing antibacterial treatment, or people with a short life expectancy won't be able to participate. Throughout the trial, participants can expect close monitoring and support from the research team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \>18 years
• • C. difficile PCR in feces positive and clinical symptoms of enteritis.
• • Full resolution of diarrhea during antibiotic treatment for C. difficile
• • No other ongoing antibacterial treatments.
• • No ongoing probiotics.
• • Signed informed consent.
• Exclusion Criteria:
• • Pregnant
• • Ongoing need for antibacterial treatment
• • Life expectancy \< 1 year
• • Prior C. difficile infection in preceding 3 months
• • Unable to provide written consent, due to dementia for example.
• • Fecal incontinence i.e. inability to retain enema.